# Axe Compute Inc.: financial statements, quarterly

AGPU · Nasdaq · CIK 1446159 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agpu.md) · [Financials](/companies/agpu/financials.md) · [Filings](/companies/agpu/filings.md) · [Insiders](/companies/agpu/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agpu/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.7](/filings/0001171843-24-006292.md) | [0.3 d](/filings/0001171843-25-001863.md) | [0.0](/filings/0001171843-25-003182.md) | [0.1](/filings/0001171843-25-005375.md) | [0.0](/filings/0001171843-25-007342.md) | [0.0 d](/filings/0001171843-26-002094.md) | [0.1](/filings/0001171843-26-003484.md) | [0.0](/filings/0001171843-26-005556.md) | [0.0](/filings/0001171843-25-007342.md) | [0.0 d](/filings/0001171843-26-002094.md) | [0.0](/filings/0001171843-26-003484.md) | [3.2](/filings/0001171843-26-005556.md) |
| Cost of revenue | $m | [0.1](/filings/0001171843-24-006292.md) | [0.2 d](/filings/0001171843-25-001863.md) | [0.0](/filings/0001171843-25-003182.md) | [0.0](/filings/0001171843-25-005375.md) | [0.0](/filings/0001171843-25-007342.md) | [0.0 d](/filings/0001171843-26-002094.md) | [0.0](/filings/0001171843-26-003484.md) | [0.0](/filings/0001171843-26-005556.md) | [0.0](/filings/0001171843-25-007342.md) | [0.0 d](/filings/0001171843-26-002094.md) | [0.0](/filings/0001171843-26-003484.md) | [3.0](/filings/0001171843-26-005556.md) |
| Gross profit | $m | [0.6](/filings/0001171843-24-006292.md) | [0.1 d](/filings/0001171843-25-001863.md) | [(0.0)](/filings/0001171843-25-003182.md) | [0.1](/filings/0001171843-25-005375.md) | [(0.0)](/filings/0001171843-25-007342.md) | [0.8 d](/filings/0001171843-25-001863.md) | [0.1](/filings/0001171843-25-003182.md) | [(0.0)](/filings/0001171843-25-005375.md) | [(0.0)](/filings/0001171843-25-007342.md) | not reported | not reported | not reported |
| Research and development | $m | [0.0](/filings/0001171843-23-007043.md) | [0.0 d](/filings/0001171843-25-001863.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.7)](/filings/0001171843-24-006292.md) | [(3.0) d](/filings/0001171843-25-001863.md) | [(3.6)](/filings/0001171843-25-003182.md) | [(2.5)](/filings/0001171843-25-005375.md) | [(2.2)](/filings/0001171843-25-007342.md) | [(2.1) d](/filings/0001171843-26-002094.md) | [(2.3)](/filings/0001171843-26-003484.md) | [(2.7)](/filings/0001171843-26-005556.md) | [(3.3)](/filings/0001171843-25-007342.md) | [(173) d](/filings/0001171843-26-002094.md) | [(7.7)](/filings/0001171843-26-003484.md) | [(17.3)](/filings/0001171843-26-005556.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0 d](/filings/0001171843-23-007043.md) | [0.0 d](/filings/0001171843-25-001863.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.2)](/filings/0001171843-24-006292.md) | [(3.5) d](/filings/0001171843-25-001863.md) | [(4.2)](/filings/0001171843-25-007342.md) | [(3.2)](/filings/0001171843-25-007342.md) | [(3.1)](/filings/0001171843-25-007342.md) | [(2.2) d](/filings/0001171843-26-002094.md) | [(2.4)](/filings/0001171843-26-005556.md) | [(2.1)](/filings/0001171843-26-005556.md) | [(77.7)](/filings/0001171843-25-007342.md) | [(151) d](/filings/0001171843-26-002094.md) | [(7.7)](/filings/0001171843-26-005556.md) | [(17.2)](/filings/0001171843-26-005556.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.78)](/filings/0001171843-24-006292.md) | not reported | [(1.04)](/filings/0001171843-25-003182.md) | [(0.68)](/filings/0001171843-25-005375.md) | [(7.26)](/filings/0001171843-25-007342.md) | not reported | [(5.12)](/filings/0001171843-26-003484.md) | [(0.23)](/filings/0001171843-26-005556.md) | [(107.25)](/filings/0001171843-25-007342.md) | not reported | [(0.36)](/filings/0001171843-26-003484.md) | [(0.87)](/filings/0001171843-26-005556.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.9](/filings/0001171843-23-007043.md) | [8.7](/filings/0001171843-25-001863.md) | [5.2](/filings/0001171843-24-002875.md) | [5.3](/filings/0001171843-24-004757.md) | [3.1](/filings/0001171843-24-006292.md) | [0.6](/filings/0001171843-26-002094.md) | [3.1](/filings/0001171843-25-003182.md) | [0.5](/filings/0001171843-25-007342.md) | [0.2](/filings/0001171843-25-007342.md) | [10.8](/filings/0001171843-26-005556.md) | [6.9](/filings/0001171843-26-003484.md) | [21.9](/filings/0001171843-26-005556.md) |
| Current assets | $m | [13.5](/filings/0001171843-23-007043.md) | [10.1](/filings/0001171843-25-001863.md) | [6.6](/filings/0001171843-24-002875.md) | [6.9](/filings/0001171843-24-004757.md) | [4.6](/filings/0001171843-24-006292.md) | [2.2](/filings/0001171843-26-002094.md) | [3.5](/filings/0001171843-25-003182.md) | [1.2](/filings/0001171843-25-005375.md) | [1.1](/filings/0001171843-25-007342.md) | [42.8](/filings/0001171843-26-005556.md) | [37.6](/filings/0001171843-26-003484.md) | [56.1](/filings/0001171843-26-005556.md) |
| Total assets | $m | [18.2](/filings/0001171843-23-007043.md) | [14.4](/filings/0001171843-25-001863.md) | [10.6](/filings/0001171843-24-002875.md) | [10.6](/filings/0001171843-24-004757.md) | [7.5](/filings/0001171843-24-006292.md) | [5.0](/filings/0001171843-26-002094.md) | [5.9](/filings/0001171843-25-003182.md) | [3.4](/filings/0001171843-25-005375.md) | [3.1](/filings/0001171843-25-007342.md) | [52.9](/filings/0001171843-26-005556.md) | [45.2](/filings/0001171843-26-003484.md) | [100](/filings/0001171843-26-005556.md) |
| Current liabilities | $m | [4.2](/filings/0001171843-23-007043.md) | [4.0](/filings/0001171843-25-001863.md) | [4.5](/filings/0001171843-24-002875.md) | [4.6](/filings/0001171843-24-004757.md) | [3.8](/filings/0001171843-24-006292.md) | [3.6](/filings/0001171843-26-002094.md) | [4.6](/filings/0001171843-25-003182.md) | [3.8](/filings/0001171843-25-007342.md) | [79.5](/filings/0001171843-25-007342.md) | [4.3](/filings/0001171843-26-005556.md) | [4.2](/filings/0001171843-26-003484.md) | [38.7](/filings/0001171843-26-005556.md) |
| Total liabilities | $m | [6.5](/filings/0001171843-23-007043.md) | [6.1](/filings/0001171843-25-001863.md) | [6.5](/filings/0001171843-24-002875.md) | [6.5](/filings/0001171843-24-004757.md) | [5.5](/filings/0001171843-24-006292.md) | [5.2](/filings/0001171843-26-002094.md) | [6.0](/filings/0001171843-25-003182.md) | [5.1](/filings/0001171843-25-005375.md) | [80.6](/filings/0001171843-25-007342.md) | [5.2](/filings/0001171843-26-005556.md) | [5.0](/filings/0001171843-26-003484.md) | [66.3](/filings/0001171843-26-005556.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [11.7](/filings/0001171843-24-006292.md) | [8.3](/filings/0001171843-26-002094.md) | [4.1](/filings/0001171843-25-007342.md) | [4.1](/filings/0001171843-25-007342.md) | [2.0](/filings/0001171843-26-002094.md) | [(0.2)](/filings/0001171843-26-005556.md) | [(0.1)](/filings/0001171843-26-005556.md) | [(1.7)](/filings/0001171843-26-005556.md) | [(77.4)](/filings/0001171843-25-007342.md) | [47.7](/filings/0001171843-26-005556.md) | [40.3](/filings/0001171843-26-005556.md) | [34.0](/filings/0001171843-26-005556.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.1) d](/filings/0001171843-23-007043.md) | [(3.1) d](/filings/0001171843-24-001694.md) | [(3.4)](/filings/0001171843-24-002875.md) | [(3.2) d](/filings/0001171843-24-004757.md) | [(1.4) d](/filings/0001171843-25-007342.md) | [(2.1) d](/filings/0001171843-26-002094.md) | [(1.0)](/filings/0001171843-26-003484.md) | [(3.3) d](/filings/0001171843-26-005556.md) | [(1.7) d](/filings/0001171843-25-007342.md) | [(3.9) d](/filings/0001171843-26-002094.md) | [(3.7)](/filings/0001171843-26-003484.md) | [21.1 d](/filings/0001171843-26-005556.md) |
| Capital expenditure | $m | [(0.2) d](/filings/0001171843-24-006292.md) | [(0.0) d](/filings/0001171843-25-001863.md) | [0.0](/filings/0001171843-25-003182.md) | [0.0 d](/filings/0001171843-25-005375.md) | [0.0 d](/filings/0001171843-25-007342.md) | [0.0 d](/filings/0001171843-26-002094.md) | [0.0](/filings/0001171843-26-003484.md) | [0.0 d](/filings/0001171843-26-005556.md) | [0.0 d](/filings/0001171843-25-007342.md) | [0.0 d](/filings/0001171843-26-002094.md) | [0.0](/filings/0001171843-26-003484.md) | [17.1 d](/filings/0001171843-26-005556.md) |
| Share repurchases | $m | not reported | [0.0 d](/filings/0001171843-25-001863.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.9](/filings/0001171843-23-007043.md) | [4.0](/filings/0001171843-24-002875.md) | [4.0](/filings/0001171843-24-004757.md) | [4.0](/filings/0001171843-24-006292.md) | [4.1](/filings/0001171843-25-003182.md) | [4.7](/filings/0001171843-25-005375.md) | [0.4](/filings/0001171843-25-007342.md) | [0.5](/filings/0001171843-26-003484.md) | [9.1](/filings/0001171843-26-005556.md) | [0.7](/filings/0001171843-25-007342.md) | [21.2](/filings/0001171843-26-003484.md) | [19.7](/filings/0001171843-26-005556.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 11,591,124 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001171843-26-005556.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.